Prevalence of Crohn’s disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year.
Growing prevalence of the disease, along with increase in number of pipeline drugs, is expected to be a key factor driving the market.
In 2018, the global Crohn’s Disease Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Crohn’s Disease Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Crohn’s Disease Therapeutics development in United States, Europe and China.
The key players covered in this study
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Company Limited
Perrigo Company PLC
Gilead Sciences Inc.
UCB India Private Limited.
Market segment by Type, the product can be split into
Market segment by Application, split into
Ambulatory Surgical Centers
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Crohn’s Disease Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Crohn’s Disease Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Crohn’s Disease Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.